New hope for tough lymphoma: glofitamab under Real-World microscope
NCT ID NCT07472621
First seen Mar 23, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back quickly after initial treatment. About 20 adults will be treated as part of their normal care, and researchers will track their response and side effects. The goal is to see if glofitamab helps control the disease in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan cancer hospital
Zhengzhou, Henan, 450008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.